Zevra Therapeutics, Inc. Line of Credit Facility, Maximum Borrowing Capacity
Zevra Therapeutics, Inc. (ZVRA) had Line of Credit Facility, Maximum Borrowing Capacity of $20.00 million as of 2022-12-31, per its 10-K filed 2024-04-01.
Discontinued › Notes › Line of Credit Facility
us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity · last filed 2024-04-01
- 2022-12-31: Line of Credit Facility, Maximum Borrowing Capacity $20.00M.
- 2022-09-30: Line of Credit Facility, Maximum Borrowing Capacity $20.00M.
- 2022-06-30: Line of Credit Facility, Maximum Borrowing Capacity $20.00M.
- 2022-05-31: Line of Credit Facility, Maximum Borrowing Capacity $20.00M.
| Period end | Line of Credit Facility, Maximum Borrowing Capacity |
|---|---|
| 2022-12-31 | $20.00M 10-K · filed 2024-04-01 |
| 2022-09-30 | $20.00M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $20.00M 10-Q · filed 2022-08-12 |
| 2022-05-31 | $20.00M 10-K · filed 2024-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |